IMAB
I-Mab - ADR

1,082
Mkt Cap
$392M
Volume
1.22M
52W High
$6.79
52W Low
$0.595
PE Ratio
-6.96
IMAB Fundamentals
Price
$4.95
Prev Close
$4.55
Open
$4.70
50D MA
$4.48
Beta
1.22
Avg. Volume
1.47M
EPS (Annual)
-$0.6974
P/B
2.06
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB PR Newswire...
PR Newswire·10d ago
News Placeholder
More News
News Placeholder
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...
PR Newswire·18d ago
News Placeholder
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know
Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·23d ago
News Placeholder
What Makes IMab (IMAB) a New Buy Stock
IMab (IMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·27d ago
News Placeholder
Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice
Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2mo ago
News Placeholder
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross
Zacks·5mo ago
News Placeholder
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?
Zacks·5mo ago
News Placeholder
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member PR Newswire...
PR Newswire·10mo ago
News Placeholder
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB...
PR Newswire·10mo ago
News Placeholder
I-Mab to Participate at the Piper Sandler Healthcare Conference
I-Mab to Participate at the Piper Sandler Healthcare Conference I-Mab to Participate at the Piper Sandler Healthcare Conference PR Newswire ROCKVILLE, Md., Nov. 21, 2024 The 36th Annual Healthcare...
PR Newswire·1y ago

Latest IMAB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.